(Q27006811)

7

object named as

Frédérique Penault-Llorca

0 references

Marc van de Vijver

8

object named as

Marc van de Vijver

1 reference

5

Mitch Dowsett

1 reference

9

Giuseppe Viale

1 reference

Wedad M Hanna

1

1 reference

Josef Rüschoff

2

1 reference

Michael Bilous

3

1 reference

Renata A Coudry

4

1 reference

Robert Y Osamura

6

1 reference

language of work or name

1 reference

January 2014

1 reference

1 reference

27

1 reference

PubMed

issue

1

1 reference

PubMed

page(s)

4-18

1 reference

Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Management of small HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Gene amplification in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

HER2 status in breast cancer: experience of a Spanish National Reference Centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Implications of rarity of chromosome 17 polysomy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Genetic heterogeneity in HER2 testing may influence therapy eligibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Fast and non-toxic in situ hybridization without blocking of repetitive sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

1 reference

7 January 2021

Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

HER2 genetic heterogeneity in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021

Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.103

7 January 2021